Replimune Group (NASDAQ:REPL) Stock Price Expected to Rise, HC Wainwright Analyst Says

Replimune Group (NASDAQ:REPL) had its target price lifted by equities research analysts at HC Wainwright from $17.00 to $21.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 77.22% from the company’s previous close.

Several other research firms also recently commented on REPL. JPMorgan Chase & Co. upped their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. BMO Capital Markets raised their target price on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday, November 22nd. Finally, Jefferies Financial Group boosted their price target on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Replimune Group presently has an average rating of “Buy” and a consensus target price of $17.86.

Replimune Group Stock Up 16.9 %

Replimune Group stock opened at $11.85 on Wednesday. Replimune Group has a twelve month low of $4.92 and a twelve month high of $17.00. The stock has a market cap of $810.78 million, a P/E ratio of -3.89 and a beta of 1.28. The company’s 50-day moving average price is $12.16 and its two-hundred day moving average price is $11.24. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. As a group, analysts expect that Replimune Group will post -2.91 EPS for the current year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the sale, the chief executive officer now owns 202,014 shares in the company, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the sale, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Several hedge funds have recently modified their holdings of REPL. Point72 DIFC Ltd bought a new position in Replimune Group in the second quarter valued at about $57,000. Erste Asset Management GmbH acquired a new position in shares of Replimune Group in the third quarter valued at approximately $133,000. China Universal Asset Management Co. Ltd. raised its holdings in Replimune Group by 82.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock valued at $144,000 after buying an additional 5,926 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Replimune Group by 81.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock worth $165,000 after buying an additional 6,748 shares during the period. Finally, GSA Capital Partners LLP bought a new stake in Replimune Group during the 3rd quarter worth approximately $222,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.